Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors

NCT03647163 is registered in ClinicalTrials.gov with Vyriad, Inc. as lead sponsor.

NCT NCT03647163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03647163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors
Lead sponsor
Vyriad, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 9, 2019
Completion date
September 30, 2025
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma, non small cell lung cancer, renal cell carcinoma (rcc), solid tumor